A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
A legfontosabb adatok
- Ki végzi
- Exelixis
- Hol
- Austin, Denver, Houston, Huntersville, Jefferson, Nashville, New Haven, New York és Washington D.C. (Egyesült Államok)Mind a 10 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1. fázis
- Résztvevők
- 9 fő vett részt
- Kezdés
- 2024. okt. 17.
- Befejezés
- 2025. máj. 7.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoport
- A vizsgált kezelések
- XL495
- ADC cytotoxic agents
- A regiszteradat frissítve
- 2025. június 25.
- Miért állt le
- Company Decision
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- For All Participants; Have received at least one standard therapy unless it does not exist, or available therapies are intolerable or no longer effective; For participants, who qualify for approved molecularly selected therapies such as RAS inhibitors, they must have progressed on, relapsed from, been intolerant to, ineligible, or refused those therapies
- Expansion Stage; Diagnosis of metastatic advanced UC (primary tumor: renal pelvis, ureter, urinary bladder, or urethra); At least one measurable lesion as defined by RECIST, version 1.1; Participants must be eligible for sacituzumab govitecan treatment as their next line of therapy
- At least one but no more than 3 prior lines of therapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status (0-2 for monotherapy; 0-1 for combo)
Ki nem vehet részt
- Prior anticancer treatment, including:; Radiation therapy within 2 weeks before first dose of study treatment
- Diagnosis of another cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with standard therapy
- Known brain metastases or cranial epidural disease
- Current or recent severe illness
- Known history or positive test for human immunodeficiency virus (HIV) unless meets specific criteria
- Active infection with hepatitis B virus or hepatitis C virus
- Malabsorption syndrome
- History of solid organ, autologous or allogenic stem cell transplant
- Active autoimmune disease with skin involvement
Helyszínek itt: Egyesült Államok
- Austin, TexasHospital not named in the registry
- Denver, ColoradoHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Huntersville, North CarolinaHospital not named in the registry
- Jefferson, LouisianaHospital not named in the registry
- Nashville, TennesseeHospital not named in the registry
- Nashville, TennesseeHospital not named in the registry
- New Haven, ConnecticutHospital not named in the registry
- New YorkHospital not named in the registry
- Washington D.C., District of ColumbiaHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.
A vizsgálat 3 csoportja
- Dose Escalation XL495A vizsgált kezelés
Group(s) of participants with advanced metastatic tumors who will receive increasing doses of XL495.
Kezelés: XL495
- Dose Finding XL495 + ADC cytotoxic agentsA vizsgált kezelés
Group(s) of participants with advanced metastatic tumors who will receive XL495 and Antibody drug conjugate (ADC) cytotoxic agents together at increasing doses.
Kezelés: XL495 és ADC cytotoxic agents
- Expansion XL495 + ADC cytotoxic agentsA vizsgált kezelés
Group(s) of participants with urothelial cancer who will receive XL495 and ADC cytotoxic agents at the recommended dosage(s) of expansion (RDE \[s\]) determined during the dose-escalation and dose-finding stages.
Kezelés: XL495 és ADC cytotoxic agents
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors
- A regiszteradat frissítve
- 2025. június 25.